Recombinant Antibodies for Research and Diagnostic Assay Manufacturing

WEBINAR

Recombinant Antibodies – Reverse engineering and critical immunoassay-derived raw materials for scalable and reproducible research, and diagnostic assay manufacturing.

As a combined result of increases in research and medical diagnostic immunoassay volumes, pressure on the global supply system of animal hosts and other traditional means of antibody production has grown tremendously. Specifically, the shortage of animal-derived materials because of the COVID-19 pandemic has spiked their demand, highlighting the need for sustainable and robust means of producing critical reagents.

In this presentation, the speakers will summarize the reverse engineering of critical IVD-IHC antibodies, and novel active and passive blocking products derived through novel B-cell cloning methods. These methods aim at sustainability and consistency, thereby reducing the impact on animal hosts. Our capabilities at Merck to support further recombinant antibody developments and collaborations will also be detailed.

In this webinar, you will learn:

• Reverse engineering of critical IVD-IHC antibodies
• Active and passive blocking products derived through B-cell cloning
• Our capabilities of large-scale recombinant Ab production
• Scope for collaborative manufacturing of antibodies